SCF ENCYCLOPEDIA ENTRY

FAMILIAL HYPERCHOLESTEROLEMIA (FH)

SCF LDL-RECEPTOR FAILURE & LIPID-HOMEOSTASIS SYNCHRONIZATION COLLAPSE DOSSIER

I. OFFICIAL DISEASE CLASSIFICATION

Familial hypercholesterolemia belongs to SCF Clinical Domains C9 (Cardiovascular Medicine), C2 (Cellular & Molecular Metabolism), C14 (Genetic Medicine), C6 (Metabolic Medicine), and C13 (Systems Degeneration Biology).

II. CLINICAL DEFINITION

Familial hypercholesterolemia is an inherited disorder characterized by:

• Markedly elevated LDL cholesterol
• Accelerated atherosclerosis
• Premature coronary artery disease
• Tendon xanthomas
• Vascular inflammation
• Increased risk of myocardial infarction

Primary affected systems:

• Hepatic LDL clearance systems
• Lipoprotein metabolism pathways
• Vascular endothelium
• Arterial walls
• Cholesterol homeostasis networks

Associated conditions:

• Hypercholesterolemia
• Atherosclerosis

III. MAJOR CLASSIFICATIONS

A. Heterozygous Familial Hypercholesterolemia (HeFH)

Most common form.

B. Homozygous Familial Hypercholesterolemia (HoFH)

Often causes cardiovascular disease during childhood or adolescence.

C. Compound Heterozygous FH

IV. CORE SCF ETIOPATHOGENIC THESIS

Within the Synergistic Compatibility Framework (SCF), familial hypercholesterolemia represents a systems-level collapse of:

• Lipid-clearance harmonics
• Cholesterol homeostasis equilibrium
• Endothelial communication integrity
• Vascular resilience networks
• Metabolic synchronization systems

SCF interprets FH as a decentralized metabolic communication disorder in which defective cholesterol-clearance mechanisms progressively destabilize vascular intelligence networks, leading to plaque accumulation and premature cardiovascular degeneration.

V. LDL-CLEARANCE FOUNDATION

Core Pathophysiologic Mechanisms

VI. MAJOR GENETIC CAUSES

Principal Genes

Genetic Characteristics

Associated condition:

• Autosomal dominant disorder

VII. SCF FAULT ARCHITECTURE

VIII. MULTI-OMICS PATHOGENESIS

A. Genomics

Affected pathways:

• Lipoprotein metabolism
• LDL receptor signaling
• Cholesterol trafficking
• Hepatic lipid regulation

B. Transcriptomics

Dysregulated pathways:

• Lipid metabolism
• Inflammatory signaling
• Endothelial activation
• Vascular remodeling

C. Proteomics

Observed abnormalities:

• LDL receptor deficiency
• ApoB abnormalities
• PCSK9 dysregulation
• Endothelial proteins

D. Metabolomics

Key dysfunction:

• Elevated LDL-C
• Elevated ApoB
• Oxidized LDL accumulation
• Lipid overload
• Increased oxidative stress

E. Lipidomics

Observed abnormalities:

• LDL particle accumulation
• Oxidized LDL elevation
• Foam-cell formation
• Cholesterol crystal deposition

IX. SCF PATHOGENESIS FLOW

Stage 1 — Genetic Mutation

LDL clearance pathways become impaired.

Stage 2 — LDL Accumulation

Circulating LDL-C rises substantially.

Stage 3 — Endothelial Penetration

LDL enters arterial walls.

Stage 4 — Foam Cell Formation

Atherosclerotic plaques develop.

Stage 5 — Progressive Vascular Disease

Plaque burden expands.

Stage 6 — Cardiovascular Events

Myocardial infarction, stroke, or vascular occlusion occurs.

X. SYSTEMIC CONSEQUENCES

Associated conditions:

• Coronary artery disease
• Myocardial infarction
• Peripheral artery disease

XI. RHENOVA INTERPRETATION

Project RHENOVA interprets familial hypercholesterolemia as a lipid-clearance bioenergetic destabilization syndrome.

RHENOVA Dynamics

• Cholesterol accumulation loops
• Endothelial injury cascades
• Plaque-growth amplification
• Vascular remodeling progression
• Cardiovascular synchronization collapse

RHENOVA Biomarkers

XII. DBI INTERPRETATION

The SCF Decentralized Biological Intelligence framework interprets lipid metabolism as a synchronized biological communication network coordinating:

• Cholesterol transport
• Cellular membrane maintenance
• Hormone synthesis
• Vascular health
• Metabolic adaptation

DBI Failure Features

• Lipid-traffic congestion
• Endothelial signaling fragmentation
• Metabolic communication instability
• Progressive vascular dysfunction

This transforms coordinated lipid management into chronic arterial disease.

XIII. CLINICAL MANIFESTATIONS

Cardiovascular Manifestations

• Premature coronary artery disease
• Angina
• Myocardial infarction
• Sudden cardiac death

Dermatologic Manifestations

• Tendon xanthomas
• Xanthelasma
• Arcus cornealis

Associated conditions:

• Tendon xanthoma
• Xanthelasma

Vascular Manifestations

• Carotid disease
• Peripheral artery disease
• Aortic disease

XIV. DIAGNOSTICS

Diagnostic Hallmarks

Clearance principle:

LDLR\ Dysfunction \Rightarrow LDL\ Accumulation

Atherosclerosis relationship:

Elevated\ LDL-C \Rightarrow Atherosclerotic\ Plaque

Disease progression concept:

Plaque\ Burden \Rightarrow Cardiovascular\ Disease

XV. SCF SYSTEMIC AXIS INVOLVEMENT

XVI. STANDARD OF CARE

Lipid-Lowering Therapy

Examples:

• Atorvastatin
• Rosuvastatin
• Ezetimibe

PCSK9 Inhibition

Examples:

• Evolocumab
• Alirocumab

Advanced Therapies

Examples:

• Inclisiran

XVII. SCF-PCR THERAPEUTIC ARCHITECTURE

A. Preventative (PCR-P)

Goals:

• Prevent LDL accumulation
• Protect endothelial function
• Delay plaque development

B. Curative (PCR-C)

Goals:

• Restore LDL receptor function
• Normalize cholesterol trafficking
• Eliminate pathogenic lipid accumulation

C. Restorative (PCR-R)

Goals:

• Restore vascular bioenergetics
• Improve endothelial communication
• Reduce oxidative injury
• Rebuild lipid-homeostasis synchronization harmonics

XVIII. ETHNOBIOPROSPECTING TARGETS

Traditional Chinese Medicine

• Salvia miltiorrhiza
• Crataegus pinnatifida

Ayurveda

• Commiphora mukul
• Curcuma longa

Vietnamese Thuốc Nam

• Nelumbo nucifera
• Camellia sinensis

XIX. SCF API DISCOVERY TARGETS

High-Priority Molecular Targets

• LDL receptor restoration systems
• PCSK9 modulation pathways
• ApoB reduction technologies
• Endothelial protection networks
• Anti-inflammatory vascular pathways
• Reverse cholesterol transport enhancement systems
• Lipid-homeostasis synchronization restoration platforms

XX. SCF LAYMAN’S SUMMARY

Familial hypercholesterolemia is an inherited disorder that prevents the body from efficiently removing LDL (“bad”) cholesterol from the bloodstream. As a result, cholesterol accumulates in arteries from an early age, causing premature plaque formation and dramatically increasing the risk of heart attacks, strokes, and other cardiovascular diseases. SCF interprets familial hypercholesterolemia as a systems-level lipid communication disorder involving LDL receptor dysfunction, cholesterol trafficking failure, endothelial injury, vascular inflammation, and progressive loss of synchronized lipid homeostasis.

XXI. STRATEGIC RESEARCH PRIORITIES

1. LDL receptor gene-restoration technologies
2. Advanced PCSK9-targeting systems
3. ApoB suppression therapies
4. AI-driven cardiovascular-risk forecasting platforms
5. Endothelial-protection therapeutics
6. Reverse cholesterol transport enhancement systems
7. Lipid-homeostasis synchronization restoration platforms

MASTER REGISTRY INDEX

SCF-FH-0001 — Familial Hypercholesterolemia Master Registry

SCF-FH-LDLR-0002 — LDL Receptor Dysfunction Layer

SCF-FH-LIPID-0003 — Lipid Homeostasis Failure Layer

SCF-FH-RHENOVA-0004 — Lipid Bioenergetic Destabilization Layer

SCF-FH-DBI-0005 — Metabolic Communication Failure Layer

SCF-FH-PCR-0006 — Preventative–Curative–Restorative Layer